Open Access

Stability analysis on the radioactive iodine‑labelled prostate cancer‑specific recombinant oncolytic adenovirus

  • Authors:
    • Jiahe Zhou
    • Lin Hao
    • Zhenduo Shi
    • Songyi Ning
    • Houguang He
    • Yan Zhao
    • Yang Dong
    • Zhigang Li
    • Jiuxiang He
    • Guanghui Zang
    • Conghui Han
  • View Affiliations

  • Published online on: September 19, 2017     https://doi.org/10.3892/ol.2017.6998
  • Pages:6403-6408
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: PDF 0 views | HTML 0 views
0

Abstract

The aim of the present study was to construct the 125I‑replication‑selective oncolytic adenovirus (RSOAds)‑ human telomerase reverse transcriptase (hTERT)/prostate specific antigen (PSA) nuclide‑oncolytic virus marker by labelling the hTERT/PSA double‑regulation replicative oncolytic adenovirus with 125I nuclide, and investigate the influence of viral markers under various reaction conditions on labelling efficiency. N‑bromosuccinimide (NBS) was used as the oxidizer for 125I labelling, and the best conditions for labelling were identified through the reactions between oncolytic adenovirus at various concentrations and NBS. Dosage of 125I, reaction duration, pH values and reaction volume were respectively evaluated to determine their effects on the labelling efficiency of 125I‑RSOAds‑hTERT/PSA nuclide‑oncolytic adenovirus markers. Purified nuclide‑oncolytic adenovirus markers were isolated by gel‑filtration chromatography; paper chromatography was performed to assay the radiochemical purity of 125I‑RSOAds‑hTERT/PSA markers at various time points. Radiochemical purity of 125I‑RSOAds‑hTERT/PSA was >95%, and could be maintained at 4˚C for 7 days. The best reaction conditions were set as follows: 0.5 µl of 125I (~0.2 m Ci, 7.4 MBq); 25 qg of NBS; 100 µl of 8x109 VP/ml 125I‑RSOAds‑hTERT/PSA virus solution; 30 min of reaction duration; pH 7.5; 120 µl of PBS. Labelling hTERT/PSA double‑regulation replicative oncolytic adenovirus with 125I was identified to be available, and the radiochemical purity of acquired virus markers could be maintained under specific conditions.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhou, J., Hao, L., Shi, Z., Ning, S., He, H., Zhao, Y. ... Han, C. (2017). Stability analysis on the radioactive iodine‑labelled prostate cancer‑specific recombinant oncolytic adenovirus. Oncology Letters, 14, 6403-6408. https://doi.org/10.3892/ol.2017.6998
MLA
Zhou, J., Hao, L., Shi, Z., Ning, S., He, H., Zhao, Y., Dong, Y., Li, Z., He, J., Zang, G., Han, C."Stability analysis on the radioactive iodine‑labelled prostate cancer‑specific recombinant oncolytic adenovirus". Oncology Letters 14.6 (2017): 6403-6408.
Chicago
Zhou, J., Hao, L., Shi, Z., Ning, S., He, H., Zhao, Y., Dong, Y., Li, Z., He, J., Zang, G., Han, C."Stability analysis on the radioactive iodine‑labelled prostate cancer‑specific recombinant oncolytic adenovirus". Oncology Letters 14, no. 6 (2017): 6403-6408. https://doi.org/10.3892/ol.2017.6998